scholarly journals Mentoring upcoming researchers for non-communicable diseases’ research and practice in Malawi

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Adamson S. Muula ◽  
Mina C. Hosseinipour ◽  
Martha Makwero ◽  
Johnstone Kumwenda ◽  
Prosper Lutala ◽  
...  
Keyword(s):  
Research Capacity ◽  
Communicable Diseases ◽  
Lessons Learned ◽  
National Institutes Of Health ◽  
Non Communicable Diseases ◽  
Mentorship Program ◽  
Research And Practice ◽  
Blood Institute ◽  
Research Mentorship ◽  
National Heart Lung

AbstractThe Malawi College of Medicine and its partners are building non-communicable diseases’ (NCDs’) research capacity through a grant from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health. Several strategies are being implemented including research mentorship for junior researchers interested to build careers in NCDs’ research. In this article, we present the rationale for and our experiences with this mentorship program over its 2 years of implementation. Lessons learned and the challenges are also shared.

scholarly journals National Institutes of Health Funding for Tobacco Control: 2006 and 2016

2018 ◽  
Vol 33 (2) ◽  
pp. 279-284
Author(s):  
Ashley L. Merianos ◽  
Judith S. Gordon ◽  
Kelsi J. Wood ◽  
E. Melinda Mahabee-Gittens
Keyword(s):  
Tobacco Control ◽  
Secondary Analysis ◽  
National Institutes Of Health ◽  
Fiscal Year ◽  
Topic Area ◽  
Study Objective ◽  
Frequency Distributions ◽  
Blood Institute ◽  
National Heart Lung ◽  
Nih Funding

Purpose: The study objective was to describe and compare changes in newly funded National Institutes of Health (NIH) tobacco-related awards between fiscal year (FY) 2006 and FY2016. Design: Secondary analysis of NIH data. Setting: National Institutes of Health Research Portfolio Online Reporting Tool database was used. Subjects: National Institutes of Health tobacco-related awards newly funded during FY2006 and FY2016. Measures: Search terms included tobacco, smoking, nicotine, secondhand smoke, and e-cigarettes. Grants and funding amounts were retrieved. Analysis: We calculated frequency distributions to determine the number and percentage of total NIH grants funded overall and by specific institute, and inflation-adjusted total and median funding amounts. We computed percentage differences in number of new grants, funding amounts, and percentage of funding allocated overall, and by institute. Results: There was a 187% increase in the percentage of total NIH funding allocated to new tobacco-related awards from 0.09% in FY2006 to 0.25% in FY2016. Total number of awards increased by 67% in FY2016 (n = 144; $56 015 931) compared to FY2006 (n = 86; $22 076 987), and there was a 154% increase in inflation-adjusted total funding for tobacco control. The top funding institutes were National Institute on Drug Abuse and National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism was third in FY2006; and National, Heart, Lung and Blood Institute in FY2016. Research grants were the most frequently funded. Smoking cessation was a common topic area and increased by 64%. Conclusion: NIH funding is critical for advancing the science of nicotine and tobacco research.

Lessons learned from the Pediatric Cardiomyopathy Registry (PCMR) Study Group

2015 ◽  
Vol 25 (S2) ◽  
pp. 140-153 ◽  
Author(s):  
James D. Wilkinson ◽  
Joslyn A. Westphal ◽  
Neha Bansal ◽  
Jason D. Czachor ◽  
Hiedy Razoky ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Current Knowledge ◽  
The United States ◽  
Lessons Learned ◽  
Cardiac Biomarkers ◽  
Diagnostic Strategies ◽  
Blood Institute ◽  
National Heart Lung ◽  
Pediatric Cardiomyopathy ◽  
Associated Risk Factors

AbstractCardiomyopathy is a rare disorder of the heart muscle, affecting 1.13 cases per 100,000 children, from birth to 18 years of age. Cardiomyopathy is the leading cause of heart transplantation in children over the age of 1. The Pediatric Cardiomyopathy Registry funded in 1994 by the National Heart, Lung, and Blood Institute was established to examine the epidemiology of the disease in children below 18 years of age. More than 3500 children across the United States and Canada have been enrolled in the Pediatric Cardiomyopathy Registry, which has followed-up these patients until death, heart transplantation, or loss to follow-up. The Pediatric Cardiomyopathy Registry has provided the most in-depth illustration of this disease regarding its aetiology, clinical course, associated risk factors, and patient outcomes. Data from the registry have helped in guiding the clinical management of cardiomyopathy in children under 18 years of age; however, questions still remain regarding the most clinically effective diagnostic and treatment approaches for these patients. Future directions of the registry include the use of next-generation whole-exome sequencing and cardiac biomarkers to identify aetiology-specific treatments and improve diagnostic strategies. This article provides a brief synopsis of the work carried out by the Pediatric Cardiomyopathy Registry since its inception, including the current knowledge on the aetiologies, outcomes, and treatments of cardiomyopathy in children.

scholarly journals The role of data and safety monitoring boards in implementation trials: When are they justified?

2020 ◽  
Vol 4 (3) ◽  
pp. 229-232
Author(s):  
Kevin Fiscella ◽  
Mechelle Sanders ◽  
Tameir Holder ◽  
Jennifer K. Carroll ◽  
Amneris Luque ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Safety Monitoring ◽  
National Institutes Of Health ◽  
Phase Iii ◽  
Blood Institute ◽  
Phase Iii Clinical Trials ◽  
National Heart Lung ◽  
Cooperative Agreements ◽  
Monitor Data

AbstractThe National Institutes of Health requires data and safety monitoring boards (DSMBs) for all phase III clinical trials. The National Heart, Lung and Blood Institute requires DSMBs for all clinical trials involving more than one site and those involving cooperative agreements and contracts. These policies have resulted in the establishment of DSMBs for many implementation trials, with little consideration regarding the appropriateness of DSMBs and/or key adaptations needed by DSMBs to monitor data quality and participant safety. In this perspective, we review the unique features of implementation trials and reflect on key questions regarding the justification for DSMBs and their potential role and monitoring targets within implementation trials.

Sign in / Sign up

Export Citation Format

Share Document